507015316 12/08/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7062150

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MICHAEL H. KAGEY	01/24/2018
CYNTHIA A. SIRARD	01/24/2018

RECEIVING PARTY DATA

Name:	LEAP THERAPEUTICS, INC.	
Street Address:	47 THORNDIKE STREET	
Internal Address:	SUITE B1-1	
City:	CAMBRIDGE	
State/Country:	MASSACHUSETTS	
Postal Code:	02141	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16345191

CORRESPONDENCE DATA

Fax Number: (617)832-7000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6178321000

Email: sjammal@foleyhoag.com, patentdocketing@foleyhoag.com

Correspondent Name: SUSAN M. ABELLEIRA
Address Line 1: 155 SEAPORT BLVD
Address Line 2: FOLEY HOAG LLP

Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	DCQ-00401
NAME OF SUBMITTER:	SANDRA JAMMAL
SIGNATURE:	/Sandra Jammal/
DATE SIGNED:	12/08/2021

Total Attachments: 4

source=DCQ-00401_ASG#page1.tif source=DCQ-00401_ASG#page2.tif source=DCQ-00401_ASG#page3.tif

PATENT 507015316 REEL: 058332 FRAME: 0048

source=DCQ-00401_ASG#page4.tif

PATENT REEL: 058332 FRAME: 0049

Joint

ASSIGNMENT

WHEREAS, we, Michael H. Kagey and Cynthia A. Sirard, have invented a certain improvement in Use of Beta-Catenin as a Biomarker for Treating Cancers using Anti-DKK-I Antibody described in an application for Patent,

	the specification of which is about to be filed in the United States Patent Office (use for utility (37 CFR § 1.53(b)) and design filings only);
	is about to be filed in the United States Patent Office as a Provisional Application
	the specification of which is United States Application No. [], filed [];
\boxtimes	the specification of which is a Patent Cooperation Treaty Application, International Application No. PCT/US2017/058555, filed October 26, 2017, which designates the United States of America [and is assigned United States Application No.];
	which was patented under United States Patent No. [].

WHEREAS, Leap Therapeutics, Inc. (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the State of Delaware, and having a usual place of business at 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141, US, desires to confirm its interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, the entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention as described in said application, together with the entire right, title and interest in and to said application and such Letters Patent as may issue on said invention; said invention, application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent. We hereby acknowledge that this assignment, being of the entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for any and all related provisional and nonprovisional, international and national phase applications, including any and all substitution, reissue, divisional, continuation, and continuation-in-part applications, and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein; we hereby expressly authorize the filing of an International Patent Application under the

B4762094.1

Docket No. DCQ-00425

Patent Cooperation Treaty which corresponds to and claims the priority of the above-identified application;

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of any future applications including substitution, reissue, divisional or continuation, continuation-in-part applications, and all related provisional and nonprovisional, international and national phase applications, and preliminary or other statements and the giving of testimony in any interference or other proceeding in which said invention or any application or patent directed thereto may be involved:

AND, we do hereby authorize and request each Patent Office and the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said invention to said ASSIGNEE, its successors, assigns, and legal representatives.

IN TESTIMONY WHEREOF, we have hereunto set our hands and affixed our seals the date set forth below.

. 3 .

Inventor's Signature:	Michael H. Kagey
State/Commonwealth of MA County of Michigs On this 24th day of 10 public, personally appeared Michae	<u>ШІДУУ — 20 (%</u> , before me, the undersigned notary sl H. Kagey,
personally known to me, or	
	actory evidence of identification, which was 251747433, exp.: 10/7/2020
to be the person whose name was si acknowledged that he/she signed th	igned on the foregoing instrument in my presence, and e foregoing instrument as his/her free act and deed.
(SEAL)	Notary Public ALA HOLL (Intername)
JONATHAN GOULD MILLER dary Public, Commonwealth of Massachusetts My Commission Expires March 1, 2024	My Commission expíres <u>& / / / / / / / / / / / </u>

~3 ×

	Cynthia A. Sirard
State/Commonwealth	·
of <u>MA</u> County of Middle X	
	Super.
	Jauua Nu 2018, before me, the undersigned notary
public, personally appeared Cy	nthia A. Sirwid,
personally known to me	, or
proved to me through sa	tisfactory evidence of identification, which was
	15e, 584782927, exp; 8/23/2018
•	
	as signed on the foregoing instrument in my presence, and d the foregoing instrument as his/her free act and deed.
ackiniwicugen mai neisne signe	a the folegoing institution as his/her free act and deed.
(SEAL)	Notary Public MATH LINE
	Joues and Could Will (Y (print name)
: 1	
JONATHAN GOULD MILLER	My Compussion expires 3 / 1 / 24

~ 4 ~

B4762094.1

My Committin a Expires March 1, 2024